問卷

TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of General Internal Medicine

Division of Family Medicine

更新時間:2023-09-19

徐華穗Hsu, Hua-Shui
  • Co-Principal Investigator
  • Clinical Trial Experience (year) -13 years -4 個月
  • D8044@mail.cmuh.org.tw

篩選

List

21Cases

2021-04-30 - 2022-07-14

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Terminated3Sites

2023-01-30 - 2026-05-29

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2023-09-15 - 2025-10-22

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting2Sites

Terminated3Sites

2024-01-01 - 2026-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2024-01-01 - 2025-12-31

Phase IV

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Terminated11Sites

2026-03-01 - 2029-01-25

Phase III

Not yet recruiting
A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)
  • Condition/Disease

    Osteoarthritis 、Overweight or Obesity

  • Test Drug

    預充填式注射劑 預充填式注射劑

Participate Sites
7Sites

Recruiting7Sites

2026-03-01 - 2030-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes
  • Condition/Disease

    Obesity or Overweight 、Type 2 Diabetes Mellitus

  • Test Drug

    注射劑

Participate Sites
8Sites

Not yet recruiting1Sites

2026-03-01 - 2030-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes
  • Condition/Disease

    Obesity or Overweight

  • Test Drug

    注射劑

Participate Sites
8Sites

Not yet recruiting1Sites

2026-07-01 - 2029-12-30

Phase III

Not yet recruiting
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (Embold)
  • Condition/Disease

    Weight Management

  • Test Drug

    膜衣錠

Participate Sites
10Sites

Not yet recruiting10Sites

2026-08-01 - 2028-12-31

Phase III

Not yet recruiting
A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)
  • Condition/Disease

    Obesity or Overweight

  • Test Drug

    注射液

Participate Sites
11Sites

Not yet recruiting1Sites

1 2 3